StockData
Adaptimmune Therapeutics PLC logo

Adaptimmune Therapeutics PLC (ADAPY) stock analysis

ADAPYOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2025, quarter ended Jun 30, 2025Last filing: 10-Q on Aug 13, 2025Score 3/30
$0.04+0.00 (+9.38%)

Close on Oct 19, 2026Market cap $55.46MP/E –Yield –

StockData Score

Prices as of Nov 11, 2026How the score works

Value0Growth1Performance1Health1Dividend0

Weak3 of 30 checks passed

Adaptimmune Therapeutics passes 3 of the 30 checks behind our score; 20 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
0/6
Growth
1/6
Past performance
1/6
Financial health
1/6
Dividend
0/6

What stands out

  • Revenue growing 10%+ a year

    Revenue grew 207% a year over the last three fiscal years.

  • Net margin above its 5-year average

    Net margin was -261% over the last twelve months, against a 5-year average of -1339%.

  • Short-term assets cover short-term debts

    Current assets are 1.52 times current liabilities.

What to watch

  • Return on equity under 15%

    Return on equity was -1341% over the last twelve months and averaged -138% over five years; we look for 15% on both.

  • Interest not well covered

    Operating income covers interest expense -29.0 times; we look for at least 5.

  • Debt not well covered by cash flow

    Operating cash flow over the last twelve months equals -740% of total debt; we look for at least 20%.

  • Growing slower than the industry

    Revenue grew -54.0% over the last twelve months; the Drugs median is 8.0%.

Valuation0/6

  • P/E against its history

    Not enough price and earnings history to compare.

  • P/E against the industry

    Needs positive earnings and enough profitable companies in the industry.

  • EV/EBITDA against its history

    Needs positive EBITDA and price history.

  • P/B against the industry

    Needs positive book value.

  • Price against fair value

    We could not estimate a fair value: it needs at least two valuation methods with positive inputs.

  • Margin of safety

    Depends on the fair value estimate.

Growth1/6

  • Revenue growing 10%+ a year

    Revenue grew 207% a year over the last three fiscal years.

  • EPS growth over 3 years

    Needs positive EPS three years ago and today.

  • Earnings acceleration

    Needs positive net income now, a year ago and five years ago.

  • Growing slower than the industry

    Revenue grew -54.0% over the last twelve months; the Drugs median is 8.0%.

  • Company guidance

    No outlook found in earnings releases from the last twelve months.

  • Gross margin trend

    This company does not report gross profit.

Past performance1/6

  • Return on equity under 15%

    Return on equity was -1341% over the last twelve months and averaged -138% over five years; we look for 15% on both.

  • Return on invested capital

    Needs operating income and invested capital.

  • Return on equity below the industry

    Adaptimmune Therapeutics's return on equity of -1341% is below the Drugs median of -58.9%.

  • Earnings over 5 years

    Needs positive net income five years ago and in the latest year.

  • Net margin above its 5-year average

    Net margin was -261% over the last twelve months, against a 5-year average of -1339%.

  • Net margin below the industry

    Adaptimmune Therapeutics's net margin of -261% is below the Drugs median of -53.0%.

Financial health1/6

  • Debt level

    Needs debt and equity figures.

  • Debt trend

    Needs a balance sheet from five years ago with positive equity.

  • Debt not well covered by cash flow

    Operating cash flow over the last twelve months equals -740% of total debt; we look for at least 20%.

  • Interest not well covered

    Operating income covers interest expense -29.0 times; we look for at least 5.

  • Short-term assets cover short-term debts

    Current assets are 1.52 times current liabilities.

  • Bankruptcy risk (Altman Z)

    Needs market value, working capital and retained earnings.

Dividend0/6

  • No dividend

    Adaptimmune Therapeutics has not paid a dividend in the last twelve months.

  • Yield against Treasuries

    No dividend.

  • Yield against the market

    No dividend.

  • Dividend stability

    No dividend.

  • Earnings cover

    No dividend.

  • Cash-flow cover

    No dividend.

Scores of similar companies

Fair value

How we estimate it

We don't publish a fair value for Adaptimmune Therapeutics. It needs a US-dollar share price, at least two valuation methods with positive inputs (earnings, EBITDA, book value or sales) and, for companies with several share classes, classes that trade at the same price.

Valuation over time

Using the earnings and balance sheet published at each date, not today's.

  • P/B at month end
  • Own 5-year median 13.2
  • Drugs median 2.3

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Margins

Share of revenue, fiscal years 2013 to 2024

Operating margin

-38.6%+12418.6 pts over 5 years

Net margin

-39.8%+12185.3 pts over 5 years

See a number that looks wrong?